Category: Clinical Trial Update Region: North America · United States Company: Astrazeneca Lp

AstraZenecas dapagliflozin shown to reduce CV fatality in DELIVER phase III trial

AstraZenecas dapagliflozin shown to reduce CV fatality in DELIVER phase III trial
AstraZeneca

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!